Farxiga® (dapagliflozin)
for Heart Failure

Farxiga (dapagliflozin) is an oral SGLT2 inhibitor that improves blood sugar control in type 2 diabetes, reduces heart failure-related risks, and slows kidney disease progression. It works by preventing glucose reabsorption in the kidneys, increasing its excretion, and reducing sodium reabsorption to support heart and kidney function.

Heart